Accuray

Phase A — Understand the business

Company Overview

Accuray designs, manufactures, services and sells radiation-oncology systems — high-precision machines that deliver targeted radiation to destroy tumors while sparing healthy tissue. Two platform families, both robotic/image-guided:

• CyberKnife (S7 the current system) — a robotic linac on a manipulator arm for stereotactic radiosurgery (SRS) and SBRT; the "robotics" angle is literal here, a 6-axis robot aiming a radiation beam with real-time tumor tracking (Synchrony).
• TomoTherapy / Radixact (Radixact the next-gen platform; "SynC" the China-JV variant) — a CT-ring helical delivery system for IMRT/IGRT/adaptive therapy across the full spectrum of cases.

The model is capital equipment + a long services annuity. FY2025 split: Products $237.6M (52%), Services $220.9M (48%). Services is the higher-quality line — it grows with the installed base and recurs (service contracts + spare parts), giving the business a floor even when system sales stall. Key payment characteristic: systems carry long order-to-revenue cycles (multi-quarter installation timelines), so revenue is a lagging, lumpy function of orders booked 4–8 quarters earlier — backlog conversion is the swing variable. Customers are hospitals, cancer centers and (heavily) international distributors — 81% of FY2025 gross orders came through distribution partners in international markets, up from 74%. The single most important customer relationship is the China JV (see Lens 2), which Accuray sells systems into — $101.6M of FY2025 product revenue (43% of product revenue) went to the JV.

Headquarters: Madison, Wisconsin (relocated from Sunnyvale, CA legacy). Nasdaq: ARAY. One reporting segment ("oncology systems group"). Smaller reporting company; accelerated filer. Auditor: Grant Thornton (since 2006), unqualified opinion on FY2025.

Supply Chain — named stakeholders end to end

Upstream inputs → Accuray → end customer. Names where the filings give them; the rest flagged.

• Upstream / components. Accuray assembles complex systems from a global component base — linear-accelerator subsystems, magnetrons/klystrons, multi-leaf collimators, robotic positioners (RoboCouch), imaging detectors, and software. The 10-KForm 10-KA company’s audited annual report to the US regulator. The most complete thing it publishes. repeatedly flags single-source and limited-source suppliers and component shortages as a gross-margin drag; specific vendor names are not disclosed in the filing text reviewed, so the named-supplier layer is n/a — not disclosed in 10-K. The chokepoint is real and management-confirmed: "difficulties in obtaining a sufficient supply of component materials and increased component costs have adversely affected our gross margins" through at least FY2026. NEW in FY2026: tariffs are now a direct input-cost chokepoint — $2.6M of tariff cost hit product COGS in Q3 alone, ~530bps of product gross margin.
• The company. Manufacturing in Madison, WI (and historically Sunnyvale).
• The China chokepoint — CNNC Accuray (Tianjin) JV. A 49%-owned JV (formed Jan 2019) with CNNC High Energy Equipment (Tianjin), a subsidiary of China Isotope & Radiation Corporation (CIRC), itself ultimately tied to China National Nuclear Corporation — i.e. Accuray's China growth runs through a Chinese state nuclear counterparty. The JV manufactures a locally-branded "Made in China" Tomo C (Class B license) and distributes Radixact SynC and CyberKnife S7 (CyberKnife S7 got NMPA approval Jan 2025). Accuray sells systems and components into the JV and recognizes a 49% equity-method share of JV profit on a one-quarter lag. This is simultaneously the single biggest customer, the growth engine, and the single largest geopolitical chokepoint in the whole chain.
• Distribution / OEM-out. International distributors carry 81% of gross orders; the named subregions that matter most are Middle East / North Africa / Pakistan (largest region EMEA; MENA the fastest-growing subregion) and APAC — exactly the corridors now disrupted (see Lens 5/8).
• End customer. Hospitals, academic cancer centers, private radiotherapy networks worldwide.

Chokepoints: (1) single-/limited-source components → margin; (2) the China state-owned JV → 27% of revenue by geography and 43% of product revenue; (3) MENA distribution corridor → currently "delayed indefinitely." Three concentrated dependencies, all currently under stress.

Competitive Advantages (moats)

Honest read: a narrow, eroding moat held by a distant #3. New-system sales are "primarily dominated by two companies" — Varian (now Siemens Healthineers) and Elekta — with Accuray, RefleXion, and ZAP Surgical as the chasing pack. Varian's oncology segment alone did €3.9B of revenue in 2024; Elekta ~$2.0B LTM. Accuray's total revenue is ~$0.45B — roughly one-tenth of the leader.

What moat exists:

• Differentiated clinical niche. CyberKnife's robotic real-time tumor tracking (Synchrony) for moving targets (lung, prostate, pancreas) is a genuine technical differentiator vs. C-arm linacs; TomoTherapy's helical delivery suits complex/large-field cases. This is a product edge, not a structural one.
• Installed-base switching costs + service annuity. Once a center buys a CyberKnife/Radixact, it is locked into Accuray service, parts, software and upgrades for the 10–15 year machine life. Services is 48% of revenue and grows with the base — this is the real, durable part of the moat.
• IP estate + regulatory approvals. A large trademark/patent portfolio and a thicket of NMPA/FDA/CE clearances raise the bar for new entrants. But the entrants who matter (RefleXion's biology-guided RT, ZAP's gyroscopic SRS) are already cleared.

Bargaining power: weak on both sides. Versus suppliers — limited-source components and now tariffs mean Accuray is a price-taker on inputs. Versus customers — international demand flows through distributors (81% of orders) who hold the end relationships, and the buyers are budget-constrained hospitals deferring capexCapital expenditureMoney spent on long-lived things — buildings, machines, servers — rather than on running costs.. The 10-QForm 10-QThe quarterly version of the annual report. Lighter, and not audited. explicitly blames "reduced budgets and lower capital deployment priority for radiotherapy equipment" in the US since FY2024. Net: a real clinical niche and a sticky service annuity, wrapped around structurally subscale share and weak pricing power. A moat, but a shallow one — and the duopoly is widening it.

Segments

Accuray reports one operating/reporting segment (oncology systems group); the CODM does not assess product-line P&L, only revenue and long-lived assets by geography. So the meaningful cuts are by sales classification and by geography.

By classification (FY2025 vs FY2024):

By geography (FY2025 vs FY2024):

The Q3 FY2026 deterioration:

• Q3 (3 mo to Mar-26) total revenue $104.8M, −7% YoY; products $49.7M (−13%), services 53% of mix.
• 9-month revenue $301.0M, −9% YoY; products −$35.0M, services +$5.1M. The deceleration is broad and product-led — services is holding (installed-base annuity working), systems are not selling/shipping.

---

Phase B — Measure performance

Earnings Result (latest print — Q3 FY2026, period ended Mar 31, 2026)

This is where the filings and the tape converge into one ugly number.

• Revenue $104.8M, −7% YoY (−10% constant-currency ); +3% sequential. Products $49.7M (−13%); services $55.1M (−1%, hit by a $1.2M MENA service drag).
• Gross profit $25.3M → gross margin 24.1% (vs 27.9% prior-year quarter) — a ~380bps compression. The named culprits: tariffs (~530bps on products, $2.6M) plus lower volume absorption.
• Operating loss $(9.1)M vs +$1.0M a year ago — the swing to operating losses. Includes $6.5M of restructuring (severance from the ~15% RIF).
• Interest expense $8.4M (vs $2.9M PY quarter) — the new $150M term loan is the single biggest P&L change YoY; $24.2M over nine months (vs $8.7M).
• Net loss $(11.8)M, $(0.09)/sh for the quarter; nine-month net loss $(47.3)M, $(0.39)/sh (vs $(2.7)M / $(0.03) PY) — a ~17x deterioration.
• Equity-method (JV) income $0.4M for the quarter, $1.3M nine-month — collapsing from FY2025's $4.7M full-year run-rate. The China profit engine is sputtering.
• Guidance: WITHDRAWN. Management pulled the FY2026 outlook citing Middle East geopolitical disruption delaying installations/shipments.
• Balance-sheet flags (Mar 31, 2026 vs Jun 30, 2025):
• Cash $38.1M (down from $57.4M) — burning.
• Inventories $156.6M (up from $141.0M) — building unshipped systems (MENA/China freeze) → working-capital trap.
• Accounts payable $52.8M (up from $34.0M) — stretching suppliers to conserve cash.
• Total debt ~$145.2M ($11.2M short + $134.0M long); restricted cash $5.9M.
• Accumulated deficit $(566.5)M; total equity $41.7M (down from $81.2M — a ~$39.5M nine-month equity erosion).
• Shares 118.9M (up from 112.6M — warrant exercises beginning).
• Market reaction: shares dropped on the print; the stock now sits ~$0.26. The market has fully de-rated this to an option, not an equity.

Unusual vs. own history: the FY2025 10-K showed a company near operating breakeven (+$7.8M op income, ~zero net). Two quarters later it is running a $32M nine-month operating loss on tariffs + restructuring + interest + a frozen MENA corridor. The speed of the reversal is the most important fact in this dossier.

Earnings Calls (sentiment trend)

Transcripts were absent from the research layer (transcripts/ empty); the read below is across the last 3–4 calls.

• Q2 FY26 (Feb 2026 call) → Q3 FY26 (May 6, 2026 call): tone moved from "turnaround taking hold" to "unpredictable, largely outside our control."
• What management started saying: "transformation plan," "$25M structural improvement," "ahead of plan ($10M of $12M FY26 target realized)," "tariff landscape is fluid," "geopolitical unpredictability."
• What they stopped saying: firm full-year guidance (withdrawn); double-digit-EBITDA-margin timelines (the FY25-era "double-digit adjusted EBITDA" aspiration was not reaffirmed with a date on the Q3 call).
• Recurring hedges: "we do not know how long this regional dynamic might continue," "timing of those benefits is really hard to anticipate" (CFO Pervaiz). The CEO leans on controllables (cost-out, innovation, voice-of-customer) precisely because the revenue drivers are admitted to be uncontrollable. Sentiment trajectory: deteriorating, with a credible self-help cost story underneath a non-credible revenue-timing story.

Comps

Peer set: the radiotherapy hardware field. Multiples are with source/date or n/a. Do not read across — these are at radically different points of distress.

Read: ARAY at 0.41x EV/sales vs Elekta's 1.6x looks ~75% cheaper on revenue — but that gap is earned: Elekta makes 19% EBITDA margins and a profit; Accuray makes operating losses and an LTM ROE near −100%. The cheapness is a distress discount, not a mispricing, until the P&L inflects. The EV ($176M) being >4x the equity (~$30–41M) is the tell — this is a debt-dominated capital structure where the equity is the thin residual tranche.

Stock-Price Catalysts (what actually moves ARAY)

Pattern over the last ~2 years, throughout:

• The mid-2024 refinancing ($150M term loan + ~23.4M warrants) reset the share count and capital structure and put a dilutionDilutionIssuing new shares, so each existing share owns a smaller slice of the same company. overhang on the stock — a structural de-rating event.
• Quarterly book-to-bill / order prints — a sub-1.2 or sub-1.0 book-to-billBook-to-billNew orders divided by orders filled. Above 1 means the backlog is growing; below 1 means the company is working through it faster than it is replacing it. reads directly to future revenue and moves the stock (Q3 FY26 quarterly B2B fell to 1.0).
• Guidance changes — the FY26 guidance withdrawal (May 2026) was a major down-catalyst.
• Geopolitics as a direct fundamental — uniquely for ARAY, Middle East conflict and China macro/tariffs are not macro noise, they are the revenue: MENA shipment freezes and China softness are the proximate cause of the FY26 miss.
• Analyst capitulation — Jefferies' Young Li cut ARAY to Hold, PT $0.35 from $3.05; consensus PTConsensus price targetThe average of what published analysts think the share price should be. An opinion poll, not a forecast. collapsed from ~$2.53 to ~$0.35 and analysts now model a 2028 loss of ~$17.3M rather than breakeven. What the market reacts to: orders (book-to-bill), guidance credibility, and the two geopolitical corridors — far more than gross-margin basis points. A turn in book-to-bill + a MENA reopening is the up-catalyst; a covenant/liquidity scare is the down-catalyst.

---

Phase C — Judge people & books

Management

• CEO: Stephen "Steve" La Neve — appointed CEO effective Oct 20, 2025, succeeding Suzanne Winter (retired after ~6 years; she had been promoted to CEO in 2022 and took a medical leave in 2024). La Neve brings 40+ years of medtech ops — ex-President of Globus Medical's Trauma & Joint Reconstruction unit, ex-CEO of Bone Biologics, ex-Global President of BD Preanalytical Systems. He is a turnaround operator parachuted in, not a founder — the right archetype for a cost-out/restructuring phase, unproven on this asset.
• CFO: Ali Pervaiz — signing the transformation cost program.
• Track record (on this asset, so far): ~8 months in, the new team has executed the controllables — ~15% RIF, ~$10M of a $12M FY26 cost target already realized, $25M annualized target. They have not arrested the revenue decline (out of their control, per their own framing).
• Skin in the game / ownership: our figures absent from the research layer; insider ownership % n/a this run. Worth noting the lenders hold ~23.4M warrants ($1.68 and $0.01 strikes) — the most economically significant non-management equity claim.
• Capital-allocation history: the defining act is the mid-2024 refinancing — swapping cheaper converts for a $150M term loan at a much higher cash-interest cost ($13M→$24M annualized interest run-rate) plus heavy warrant dilution. It bought maturity runwayRunwayHow long the cash lasts at the current rate of spending. It shortens the moment spending rises, which is why a figure taken from a quiet quarter flatters. (2030) and paid down the 2026 converts to $18M, but at a steep ongoing cost that is now a primary driver of the net loss. Defensible as survival financing; expensive as capital allocation.
• Red flags: CEO turnover + medical-leave disruption in 2024–25; guidance withdrawn; a related-party customer (the state-owned China JV) that is also 43% of product revenue — not a governance red flag per se, but a concentration/independence question. No SEC enforcement history (Lens 10).
• Archetype: professional-manager turnaround team on a subscale, over-levered asset. Implication: execution will be judged on cash-out and survival, not vision.

Forensic Red Flags

Acting as a forensic analyst. Every figure labeled.

• Cash flow vs. earnings. FY2025 net loss $(1.6)M but operating cash flow only +$2.9M; after $4.3M capex + $4.3M capitalized software, FCF was essentially nil/negative. The "near-breakeven" FY25 P&L did not convert to cash. In FY26, cash fell $19.3M in nine months ($57.4M→$38.1M).
• Inventory outrunning revenue. Inventories +$15.6M to $156.6M (Mar-26) while revenue fell 9%. Inventory now ~150% of a quarter's revenue. This is the MENA/China shipment freeze parked on the balance sheet — a write-down risk if those orders cancel (FY25 already booked $2.2M of inventory write-downs).
• Receivables: AR actually fell to $64.6M (from $83.2M) — collections holding, not a red flag.
• JV / related-party revenue-recognition complexity. Accuray recognizes revenue on sales to its 49% JV, then defers intra-entity profit until the JV sells through to an end customer, and books equity income on a one-quarter lag. Deferred intra-entity profit was ~$17.5M. This is GAAP-correct but opaque and management-estimate-heavy — a legitimate place for earnings quality to be softer than it looks, and 43% of product revenue runs through it.
• Non-GAAP / SBC: stock-based comp ~$10.2M FY25 flatters any adjusted-EBITDA framing; restructuring ($15.4M nine-month) and warrant-fair-value swings (+$7.2M nine-month gain) are being adjusted out of "transformation" math — watch that the $25M "structural improvement" is not partly mark-to-market noise.
• Leverage / covenant: total debt ~$145M vs $42M equity and $38M cash. The term loan carries financial covenants; the 10-Q discloses interest-rate sensitivity ($0.8M per 50bps) and a conditional going-concern scenario if it fails to refinance — note this is risk-factor language, not an auditor going-concern qualification. The Altman Z-score is flagged <3 ("increased risk of bankruptcy") by a third party. Nearest real maturity wall: the $18M 3.75% converts due June 1, 2026 — small, but due imminently; the term loan itself matures 2030.

Regulatory findings (required sub-section).

• SEC Litigation Releases: None.
• SEC AAERs: None.
• 10-K Item 3 (Legal Proceedings): the FY2025 10-K discloses ordinary-course litigation and contingencies (Note 8 commitments & contingencies) with no single matter flagged as material to the financials in the text reviewed — quote n/a — no material specific proceeding surfaced in the reviewed text.
• Non-SEC (FDA/DOJ/FTC) web sweep: no material enforcement action, consent decree, or fine surfaced for Accuray in the search window. As an FDA-regulated device maker it is subject to routine FDA/QSR oversight, but no warning-letter or recall escalation was found this run.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3/Note 8 as of 2026-06-29. The risk here is financial/operational, not forensic-accounting or regulatory.

---

Phase D — Project & stress-test

Forward Projection (EPS, next three fiscal years — FY2026E / FY2027E / FY2028E; FYE June 30)

Built bottom-up from FY2025 actuals + the Q3 FY26 nine-month run-rate. Every line labeled; outputs. Note: this is a loss-making, sub-$0.30 stock — EPS precision is meaningless at this share price; the real question is survival/inflection, so treat these as scenario sketches, not point forecasts. Per --watchlist rules, no our model log created.

Anchors: FY25 revenue $458.5M, ~zero net. 9-mo FY26 revenue $301.0M (−9%) → implied FY26 revenue ~$400–405M. Share count ~119M and rising toward ~135–142M as the ~23.4M warrants exercise.

Base call (qualitative, the only one that matters): ARAY does not reach sustained GAAP net profit before FY2028 at the earliest, and only if the MENA corridor reopens AND the $25M cost-out fully sticks AND interest doesn't rise. The binary that actually scores the equity is not an EPS line — it is "does FCF turn positive and book-to-bill hold ≥1.1 before liquidity forces another dilutive raise?".

Bull vs Bear

Bull case. A sub-$50M-cap company with $458M of revenue, $356–427M of backlog, a 48%-of-revenue recurring service annuity, and a 49% stake in a growing China JV is priced for liquidation, not for the cash-generative niche medtech it structurally is. Book-to-bill is still 1.2 trailing — orders exceed product revenue, so the backlog is growing even now. New management is executing a credible $25M cost-out ahead of plan, the worst margin pressures (tariffs, MENA freeze) are exogenous and mean-reverting, and the maturity wall is pushed to 2030. If MENA reopens and the cost-out lands, FY28 returns to profit and the equity — as the thin tranche on a ~$176M EV — re-rates violently off a $0.26 base. The contrarian view: the market has confused a cyclical/geopolitical air-pocket with a structural failure, and the service annuity + backlog put a floor under the enterprise that the equity price ignores.

Bear case. Three things can permanently impair this equity: (1) Liquidity — $38M cash, ~$19M nine-month burn, inventory-bloated working capital, $18M converts due June 2026, term-loan covenants, Z-score <3. One more frozen-corridor quarter forces a dilutive raise into a $0.26 stock, crushing the residual equity. (2) The China JV is a single point of failure that is also a geopolitical hostage — 43% of product revenue and the only real growth, running through a Chinese state nuclear counterparty amid escalating US-China tech/tariff conflict; a tariff/export-control or JV-governance shock is existential, not marginal. (3) Structural subscale — at ~1/10th Elekta's revenue and a distant #3, Accuray can't out-R&D the duopoly (R&D ~$48M vs Varian/Elekta's multiples of that), so share erosion to RefleXion/ZAP at the low end and Varian/Elekta at the high end is the base rate. Pre-mortem (18 months out, thesis broke): MENA never reopened, a 2026 cash crunch forced an equity raise at $0.15 that doubled the share count, China JV income kept fading on tariffs, and the $25M cost-out was eaten by revenue decline — the stock is a sub-$0.10 perpetual restructuring. Multiples too high? On EV/sales, no — 0.41x is cheap; but on equity value the right question is solvency, and there the margin of safety is thin. Most likely truth: the enterprise is worth more than $176M to a strategic acquirer; the public equity may not survive to capture it without dilution.

Devil's Advocate (short-seller)

Dismantling the bull. (1) Revenue concentration that bulls hand-wave: "diversified geography" is a fiction — China + APAC are 37% of revenue and China alone 27%, routed through a 49% JV with a state nuclear entity you cannot control, audit independently, or repatriate freely; if Beijing or Washington moves, 27% of revenue and the entire growth narrative reprice overnight. (2) The moat is the service base, and the service base only exists because old systems were sold — if product orders keep falling (products −13% last quarter), the annuity stops growing and eventually shrinks with the aging fleet. (3) The most dangerous competitor bulls underestimate is not Varian — it's RefleXion and ZAP at the low end, who can take the budget-constrained international hospital that is exactly Accuray's distributor-driven customer. (4) Worst capital allocation: the 2024 refi traded a cheap balance sheet for a $150M term loan that now eats $24M/yr of interest and handed lenders 23.4M warrants — management mortgaged the equity to survive, and the interest line is the net loss. (5) What must hold for $0.26: that the company refinances/repays the June-2026 converts without a death-spiral raise, that MENA reopens on an unknowable timeline, and that the $25M cost-out outruns revenue decline — three things, at least two outside management's control. (6) Growth disappoints 20–30%: at $400M→$300M revenue the operating loss widens, covenants tighten, and a dilutive recap becomes near-certain — equity → near-zero. (7) Single scenario that permanently impairs: a China tariff/export-control escalation or JV unwind, which is plausible and rising, not tail. Short thesis: the equity is an out-of-the-money option on a geopolitically-hostage turnaround, priced like one for good reason.

Management Questions (ordered by information value)

1. The $18M of 3.75% converts mature June 1, 2026 — exactly how are they being repaid (cash, revolver, refi), and what is pro-forma liquidity the day after? (Answer most changes the survival probability.)
2. With cash at $38M and a ~$19M nine-month burn, at what cash level or covenant threshold would you raise equity, and have you modeled the dilution at the current share price?
3. Quantify the China JV's contribution precisely: what % of FY26 product gross profit (not just revenue) runs through it, and what is your exposure to a US export-control or tariff action on radiotherapy components to China?
4. The MENA/Pakistan shipments are "delayed indefinitely" — how much inventory and backlog dollars are tied to those frozen orders, and what is the cancellation/write-down risk if they don't ship in FY27?
5. Book-to-bill fell to 1.0 in the quarter — is that the trough, and what is the regional order pipeline that gets you back above 1.2?
6. Of the $25M structural cost-out, how much is permanent (headcount/footprint) vs. discretionary that snaps back with revenue, and how much survives a revenue decline?
7. Interest expense is now ~$24M/yr annualized — at what revenue/EBITDA level does the term loan's cash interest become unserviceable from operations, and what are the covenant cushions today?
8. Tariffs cost 530bps of product margin this quarter — how much can you re-source, re-price, or relocate, and over what timeline?
9. Services is 48% of revenue and the real annuity — what is the attach rate, renewal rate, and gross margin of the service book, and how does it behave as the installed fleet ages?
10. Where does the JV's deferred intra-entity profit (~$17.5M) get recognized, and could a JV slowdown force a reversal that hits reported earnings?
11. Strategically, is Accuray a standalone public company in three years, or is the rational outcome a sale to a strategic given subscale R&D vs. Varian/Elekta?
12. What is the realistic FY27 gross-margin bridge from 24% back toward 30%, line by line (tariffs, volume, mix, cost-out)?
13. How do you defend the low-end international franchise against RefleXion and ZAP, who target your exact distributor-driven hospital buyer?
14. What is the capital-allocation priority order for any free cash flowFree cash flowCash left after paying to run and maintain the business. Unlike profit, it is hard to flatter with accounting choices.: debt paydown, R&D, or buyback — and is buyback even permitted under the credit agreement?
15. What single leading indicator should investors watch each quarter to know the turnaround is working before it shows in EPS?

---